Adagrasib (Krazati) Approved for KRAS-Mutated NSCLC : vimars

It becomes the second KRAS-targeted therapy for use in patients with non–small cell lung cancer (NSCLC) whose tumors have this mutation.

Related Keywords

Shirishm Gadgeel , , Department Of Internal Medicine , Drug Administration , Division Of Hematology , Agilent Resolution , Internal Medicine , Henry Ford Cancer , Henry Ford Health , David Meek , Lung Cancer , Ung Carcinoma , Ancer Lung , Otolaryngology , Nt Ears , Nose , Throat , Skras , K Ras , V Ki Ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog , Gtpase Kras , Biologic Therapy , Colorectal Cancer , Small Cell Lung Cancer , Targeted Therapy , Cancer , Alignant Neoplasia , Arcinoma , Tumor , Pain Management , Lung , Abdominal Pain , Grant , Spain , Plasma , Tissue , Constipation , Diarrhea , Pneumonia ,